Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. Show more
Location: The Omeros Building, Seattle, WA, 98119, United States | Website: https://www.omeros.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
175.8M
52 Wk Range
$2.97 - $13.60
Previous Close
$3.00
Open
$2.99
Volume
1,367,327
Day Range
$2.95 - $3.20
Enterprise Value
538.4M
Cash
52.41M
Avg Qtr Burn
-35.72M
Insider Ownership
4.40%
Institutional Own.
47.30%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
Narsoplimab (OMS721) Details Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) | PDUFA Approval decision | |
Zaltenibart/OMS906 [MASP-3 inhibitor Antibody] Details Paroxysmal nocturnal hemoglobinuria | Phase 3 Update | |
Zaltenibart/OMS906 [MASP-3 inhibitor Antibody] Details Blood disorder, C3 Glomerulopathy | Phase 2 Data readout | |
OMS405 (PPARγ agonist) Details Addiction | Phase 2 Update | |
OMS527 (PDE7 inhibitor) Details Cocaine use disorder | Phase 1b Data readout | |
OMS1029 (MASP-2) Details Lectin pathway disorder | Phase 1 Update | |
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Kidney disease, Diabetic macular edema, Diabetes | Failed Discontinued | |
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Blood disorder, Rare diseases | Failed Discontinued | |
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Kidney disease, IgA nephropathy | Failed Discontinued |